These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 22531627)
1. Application of fusion protein 4D5 scFv-dibarnase:barstar-gold complex for studying P185HER2 receptor distribution in human cancer cells. Ivanova JL; Edelweiss EF; Leonova OG; Balandin TG; Popenko VI; Deyev SM Biochimie; 2012 Aug; 94(8):1833-6. PubMed ID: 22531627 [TBL] [Abstract][Full Text] [Related]
2. [Immunocytochemical visualization of P185(HER2) receptor by antibody fused with dibarnase and conjugate of barstar with colloidal gold]. Ivanova IuL; Edelweiss EF; Leonova OG; Balandin TG; Popenko VI; Deev SM Mol Biol (Mosk); 2013; 47(5):806-17. PubMed ID: 25509353 [TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts. Balandin TG; Edelweiss E; Andronova NV; Treshalina EM; Sapozhnikov AM; Deyev SM Invest New Drugs; 2011 Feb; 29(1):22-32. PubMed ID: 19789841 [TBL] [Abstract][Full Text] [Related]
4. Barnase as a new therapeutic agent triggering apoptosis in human cancer cells. Edelweiss E; Balandin TG; Ivanova JL; Lutsenko GV; Leonova OG; Popenko VI; Sapozhnikov AM; Deyev SM PLoS One; 2008 Jun; 3(6):e2434. PubMed ID: 18560598 [TBL] [Abstract][Full Text] [Related]
5. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187 [TBL] [Abstract][Full Text] [Related]
6. A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells. Glinka EM; Edelweiss EF; Sapozhnikov AM; Deyev SM Gene; 2006 Jan; 366(1):97-103. PubMed ID: 16300908 [TBL] [Abstract][Full Text] [Related]
7. AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu. Masuda K; Richter M; Song X; Berezov A; Masuda K; Murali R; Greene MI; Zhang H Oncogene; 2006 Dec; 25(59):7740-6. PubMed ID: 16785990 [TBL] [Abstract][Full Text] [Related]
8. Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody. Bergman I; Barmada MA; Griffin JA; Slamon DJ Clin Cancer Res; 2001 Jul; 7(7):2050-6. PubMed ID: 11448923 [TBL] [Abstract][Full Text] [Related]
9. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Ye D; Mendelsohn J; Fan Z Oncogene; 1999 Jan; 18(3):731-8. PubMed ID: 9989823 [TBL] [Abstract][Full Text] [Related]
10. c-erbB-2/p185-directed therapy in human lung adenocarcinoma. Snider JM; Bushnell LJ; Chen LC; Lanza LA Ann Thorac Surg; 1996 Nov; 62(5):1454-9. PubMed ID: 8893583 [TBL] [Abstract][Full Text] [Related]
11. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. De Santes K; Slamon D; Anderson SK; Shepard M; Fendly B; Maneval D; Press O Cancer Res; 1992 Apr; 52(7):1916-23. PubMed ID: 1348016 [TBL] [Abstract][Full Text] [Related]
12. Design of multivalent complexes using the barnase*barstar module. Deyev SM; Waibel R; Lebedenko EN; Schubiger AP; Plückthun A Nat Biotechnol; 2003 Dec; 21(12):1486-92. PubMed ID: 14634668 [TBL] [Abstract][Full Text] [Related]
13. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853 [TBL] [Abstract][Full Text] [Related]
14. [Targeted detecting HER2 expression with recombinant anti HER2 ScFv-GFP fusion antibody]. Gao G; Chen C; Yang Y; Yang H; Wang J; Zheng Y; Huang Q; Hu X Sheng Wu Gong Cheng Xue Bao; 2012 Aug; 28(8):1002-14. PubMed ID: 23185900 [TBL] [Abstract][Full Text] [Related]
15. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Zhang H; Wang Q; Montone KT; Peavey JE; Drebin JA; Greene MI; Murali R Exp Mol Pathol; 1999 Sep; 67(1):15-25. PubMed ID: 10493889 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. Kern JA; Torney L; Weiner D; Gazdar A; Shepard HM; Fendly B Am J Respir Cell Mol Biol; 1993 Oct; 9(4):448-54. PubMed ID: 8104437 [TBL] [Abstract][Full Text] [Related]
17. Construction and characterization of a recombinant human beta defensin 2 fusion protein targeting the epidermal growth factor receptor: in vitro study. Zhang M; Qiu Z; Li Y; Yang Y; Zhang Q; Xiang Q; Su Z; Huang Y Appl Microbiol Biotechnol; 2013 May; 97(9):3913-23. PubMed ID: 22903275 [TBL] [Abstract][Full Text] [Related]
18. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells. Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001 [TBL] [Abstract][Full Text] [Related]
19. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2). Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348 [TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]